{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:39:39Z","timestamp":1757698779320},"reference-count":12,"publisher":"Kurume Medical Journal","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2020,3,31]]},"DOI":"10.2739\/kurumemedj.ms671001","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T22:12:28Z","timestamp":1637878348000},"page":"11-16","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and Safety of Tolvaptan in Patients with Aortic Stenosis"],"prefix":"10.2739","volume":"67","author":[{"given":"KOUTATSU","family":"SHIMOZONO","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOSHIHIRO","family":"FUKUMOTO","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1445","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368:1005-1011.","DOI":"10.1016\/S0140-6736(06)69208-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-B\u00e4rwolf C et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24:1231-1243.","DOI":"10.1016\/S0195-668X(03)00201-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G et al. Guidelines on the management of valvular heart disease (version 2012) : The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33:2451-2496.","DOI":"10.1093\/eurheartj\/ehs109"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Carabello BA and Paulus WJ. Aortic stenosis. Lancet 2009; 373:956-966.","DOI":"10.1016\/S0140-6736(09)60211-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lindman BR, Bonow RO, and Otto CM. Current Management of Calcific Aortic Stenosis. Circ Res 2013; 113:223-237.","DOI":"10.1161\/CIRCRESAHA.111.300084"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Imamura T and Kinugawa K. Update of acute and long-term tolvaptan therapy. J Cardiol 2019; 73:102-107.","DOI":"10.1016\/j.jjcc.2018.10.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yamamoto T, Miura S, Shirai K, and Urata H. Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status. J Clin Med Res 2019; 11:49-55.","DOI":"10.14740\/jocmr3671"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Takasu K, Miyazaki T, Negoro K, Yatsu S, Shimizu M et al. Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients. Int Heart J 2017; 58:378-384.","DOI":"10.1536\/ihj.16-226"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Do e Z, Fukumoto Y, Sugimura K, Miura Y, Tatebe S et al. Rho-Kinase Activation in Patients With Heart Failure. Circ J 2013; 77:2542-2550.","DOI":"10.1253\/circj.CJ-13-0397"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Igata S, Tahara N, Sugiyama Y, Bekki M, Kumanomido J et al. Utility of the amplitude of RV<sub>1<\/sub>+SV<sub>5\/6<\/sub> in assessment of pulmonary hypertension. PLoS One 2018; 13:e0206856.","DOI":"10.1371\/journal.pone.0206856"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lloyd JW, Nishimura RA, Borlaug BA and Eleid MF. Hemodynamic Response to Nitroprusside in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Ejection Fraction. J Am Coll Cardiol 2017; 70:1339-1348.","DOI":"10.1016\/j.jacc.2017.07.736"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lindman BR, Zajarias A, Madrazo JA, Shah J, Gage BF et al. Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis. Circulation 2012; 125:2353-2362.","DOI":"10.1161\/CIRCULATIONAHA.111.081125"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/67\/1\/67_MS671001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T04:20:36Z","timestamp":1647058836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/67\/1\/67_MS671001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms671001","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"value":"0023-5679","type":"print"},{"value":"1881-2090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"article-number":"MS671001"}}